




GASTROESOPHAGEAL REFLUX DISEASE

Dr Peltec Angela

GERD: MONTREAL DEFINITION

“A condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications”

The Montreal definition and classification of GERD 2006

- ≥ 2 heartburn episodes/week
- Adversely affect an individual's well being

From Vakil N et al. Am J Gastroenterol 2006;101(8):1900-20.



ETIOLOGY

FACTORS ASSOCIATED WITH GERD

More likely to be a
cause of GORD



More likely to be an
effect of GORD

Genetic	Demographic	Behavioural	Comorbid
+ parental family history + GI disease/symptoms in an immediate relative	+ pregnancy + age + body mass index - educational level	+ smoking + alcohol consumption + drug therapy* - oral contraceptive, - coffee consumption	+ abdominal pain, dysphagia, dyspepsia + asthma + cough + hoarseness + angina + gall bladder disease + laryngitis + otitis + sinusitis + chest pain + anxiety/depression

+ Factor positively associated with GORD in at least one study

- Factor negatively associated with GORD in at least one study


* Drug therapy includes: anticholinergic, NSAID, aspirin, oral steroid nitrate, antirheumatic

PATHOPHYSIOLOGY OF GERD


1. Anti-Reflux Barrier
2. Esophageal Contact Time
3. Gastric contents



The Antireflux Barrier



PATHOGENESIS OF GERD



PATHOPHYSIOLOGY OF GERD

ESOPHAGEAL ACID CONTACT

1. Impaired esophageal motility
 - Dysfunctional peristalsis (aging)
 - Poor emptying (hiatal hernia)

2. Salivary function
 - Decreased salivation in sleep
 - Cigarette use <60% saliva HCO_3



PATHOPHYSIOLOGY OF GERD

GASTRIC REFLUXATE

- Hydrochloric acid
 - 40-70% Z-E patients have severe esophagitis
 - No difference in basal acid levels in GERD / esophagitis
 - Best treatment results with acid suppression Rx
- Pepsin, bile, pancreatic enzymes
 - Can injure experimental esophagus tissue
 - Effects either limited by acid or too low concentration
 - Role of bile reflux in refractory GERD controversial
- Acid rebound after PPI therapy
- Effect of H. pylori eradication ???



A decorative graphic on the left side of the slide. It features several vertical stripes in shades of brown, tan, and grey. Overlaid on these stripes are several orange circles of varying sizes, arranged in a cluster that tapers downwards.

GERD: CLINICAL FEATURES



Chronic recurrent heartburn and other symptoms, including dysphagia, hoarseness, etc.

Reports of frequent episodes of heartburn, but no other symptoms

Mild intermittent heartburn, not seen by a physician

GERD ICEBERG



TYPICAL SYMPTOMS

- Common symptoms most common when $\text{pH} < 4$
 - Heartburn
 - Belching and regurgitation
 - Hypersalivation
- May be episodic or nocturnal
- May be aggravated by meals and reclining position



Extraesophageal manifestations of GERD.

Otitis media

Frequent throat clearing

Asthma

Globus

Chronic sinusitis

Tracheobronchitis

Dental erosions

Chronic cough

Aphthous ulcers

Aspiration pneumonia

Halitosis

Pulmonary fibrosis

Pharyngitis

Chronic bronchitis

Laryngitis

Bronchiectasis

Laryngospasm

Noncardiac chest pain

Postnasal drip

Sleep apnea



"Alarm" signs that necessitate further evaluation of GERD.

Dysphagia

Odynophagia

Weight loss


Gastrointestinal (GI) bleeding

Family history of upper GI tract cancer

Anemia

Advanced age





WORKUP

GERD DIAGNOSIS: MENU

- Empiric trial
- Barium esophagram
- Endoscopy
- Manometry
- pH testing
- Impedance



EMPIRIC MEDICAL THERAPY

GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF GERD 2013 AGA

- A presumptive diagnosis of GERD can be established in the setting of **typical symptoms of heartburn and regurgitation**. **Empiric medical therapy** with a proton pump inhibitor (PPI) is recommended in this setting. (Strong recommendation, moderate level of evidence)
- Patients with **non-cardiac chest pain** suspected due to GERD should **have diagnostic evaluation before institution of therapy**. (Conditional recommendation, moderate level of evidence).
- A cardiac cause should be excluded in patients with chest pain before the commencement of a gastrointestinal evaluation (Strong recommendation, low level of evidence)



BARIUM ESOPHAGRAM

GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF GERD - 2013 AGA

- **Barium radiographs
should not be
performed to diagnose
GERD**

(Strong recommendation,
high level of evidence)



ENDOSCOPY

MANAGEMENT OF GERD: ASGE GUIDELINES

- GERD despite therapy
- Dysphagia
- Odynophagia
- Unexplained weight loss
- GI bleeding/anemia
- Choking
- Chest pain
- Mass, stricture or ulcer on imaging study
- Recurrent symptoms after antireflux surgery

From Gastrointest Endosc 2007;66:219-24.



MANOMETRY

AGA ESOPHAGEAL GERD PRACTICE GUIDELINES:


- GERD despite therapy
- Negative endoscopy
- Goals:
 - LES location
 - Peristaltic function preoperatively
 - Detection of subtle motility abnormalities
- High resolution manometry superior to conventional manometry for achalasia variants & distal esophageal spasm
- **Esophageal manometry is recommended for preoperative evaluation, but has no role in the diagnosis of GERD**

**From Kahrilas PJ et al. Gastroenterology
2008;135:1383-91.**



24-HOUR ESOPHAGEAL PH MONITORING

- Most accurate test for measuring pattern, frequency, and duration of reflux episodes
- Documents correlation between reflux episodes and symptoms
- Sensitivity (77-100%)
 - Normal in 25% of esophagitis!
- Specificity 85-100%
- Most useful when diagnosis still unclear



Dent et al. Gut. 1999;44(suppl 2):S1-S16.


IMPEDANCE

- In 1991 Silny was the first to describe multichannel intraluminal impedance (MII), a novel method of detecting intraesophageal bolus movement
- This method is based on measuring the resistance to alternating current (i.e., impedance) of the content of the esophageal lumen
- When a pair of electrodes, separated by an isolator (i.e., catheter), is placed inside the esophagus, the electrical circuit is closed by electrical charges (i.e., ions) present in the esophageal mucosa that surround the catheter
- **The conductivity of the empty esophageal lumen is relatively stable**, with the electrical circuit registering values around 2000 to 4000 ohm



IMPEDANCE

COMBINED MULTICHANNEL INTRALUMINAL IMPEDANCE AND pH CATHETER.



GI Motility online (May 2006) | doi:10.1038/gimo31



A decorative graphic on the left side of the slide. It features a series of vertical stripes in shades of brown, tan, and grey. Overlaid on these stripes are several orange circles of varying sizes, arranged in a cluster that tapers downwards.


DIFFERENTIAL DIAGNOSIS

ALTERNATIVE DIAGNOSIS IN GERD

- Coronary artery disease
- Gallstones
- Gastric /esophageal cancer
- Peptic ulcer disease
- Esophageal motility disorders
- Pill induced esophagitis
- Eosinophilic esophagitis

From Kahrilas PJ. N Engl J Med 2008;359:1700-7.






CLASSIFICATION

MONTREAL CLASSIFICATION OF GERD


GERD is a condition which develops when the reflux of gastric content causes troublesome symptoms or complications



From Vakil N et al. Am J Gastroenterol 2006;101:1900-20.


The LA Classification system for the endoscopic assessment of reflux esophagitis

Grade A



One (or more) mucosal break, no longer than 5 mm, that does not extend between the tops of two mucosal folds

Grade B




One (or more) mucosal break, more than 5 mm long, that does not extend between the tops of two mucosal folds

Grade C




One (or more) mucosal break that is continuous between the tops of two or more mucosal folds, but which involves less than 75% of the circumference

Grade D



One (or more) mucosal break that involves at least 75% of the esophageal circumference



TREATMENT

THERAPY GOALS

- **Alleviate or eliminate symptoms**
- **Diminish the frequency of recurrence and duration of esophageal reflux**
- **Promote healing – if mucosa is injured**
- **Prevent complications**



GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF GERD - 2013 AGA

- **Weight loss is recommended for GERD patients who are overweight or have had recent weight gain.**
(Conditional recommendation, moderate level of evidence)




DRUG THERAPY - ANTACIDS

Antacids with or without alginic acid

- Antacids increase LES pressure and do not promote esophageal healing
 - Neutralize gastric acid, causing alkalization
- Alginic acid (in Gaviscon) forms a highly viscous solution that floats on top of the gastric contents
- Dose as needed – typical action – 1-3 hours
- Not best choice for nocturnal symptoms because pH suppression cannot be maintained

Products: Magnesium salts, aluminum salts, calcium carbonate, and sodium bicarbonate

- Dosing: Initially 40-80 mEq
(no more than 500-600 mEq per 24 hours)



DRUG THERAPY – H₂RA's

	Cimetidine	Famotidine	Nizatidine	Ranitidine
Low dose (qd to bid)	200 mg	10 mg	75 mg	75 mg
Standard dose (bid)	400 mg	20 mg	150 mg	150 mg
High dose	400 mg qid or 800 mg bid	40 mg bid	150 mg qid	150 mg qid



DRUG THERAPY - PPI'S

○ Standard dosing

- Esomeprazole 20 mg qd
- Rabeprazole 20 mg qd (every day)
- Pantoprazole 40 mg qd
- Lansoprazole 15-30 mg qd
- Omeprazole 20 mg qd

○ Timing

- Best is 30 minutes prior to breakfast



DRUG THERAPY - PROKINETICS

Prokinetic Agents

- Enhances motility of smooth muscle from esophagus through the proximal small bowel
- Accelerates gastric emptying and transit of intestinal contents from duodenum to ileocecal valve
- Results of therapy
 - Improved gastric emptying
 - Enhanced tone of the lower esophageal sphincter
 - Stimulated esophageal peristalsis (cisapride)

Drug Therapy – Mucosal Protectants

Sucralfate

Very limited value in treatment of GERD

Comparisons

Similar healing rate to H₂RA in treatment of mild esophagitis

Less effective than H₂RAs in refractory esophagitis

Only use in mildest form of GERD



Esophageal clearance:
Cisapride

Gastric emptying:
Metoclopramide
Cisapride

Esophageal mucosal resistance:
Alginic acid,
Sucralfate

LES pressure:
Metoclopramide
Cisapride

Gastric acid:
Antacids
H2RAs
PPIs

esophagus

diaphragm

lower
esophageal
sphincter



duodenum

stomach

A decorative graphic on the left side of the slide. It features a series of vertical stripes in shades of brown, tan, and grey. Overlaid on these stripes are several orange circles of varying sizes, arranged in a cluster that tapers towards the bottom.

SURGICAL THERAPY FOR GERD

Nissen Fundoplication



Surgical Reconstruction of Esophageal Hiatus




A decorative graphic on the left side of the slide. It features a series of vertical stripes in shades of brown, tan, and grey. Overlaid on these stripes are several orange circles of varying sizes, arranged in a cluster that tapers downwards.




COMPLICATIONS OF GERD

COMPLICATIONS

- Esophagitis
- Esophageal strictures and ulcers
- Hemorrhage
- Perforation
- Aspiration
- Development of Barrett's esophagus
- Precipitation of an asthma attack



COMPLICATIONS OF GERD



BARRETT'S ESOPHAGUS



- Barrett's Oesophagus (BO) is a premalignant condition of the oesophagus defined as the presence of metaplastic columnar epithelium, which endoscopically appears as salmon pink mucosa, extending above the gastro-oesophageal junction (GOJ) and into the tubular oesophagus, thereby replacing the stratified squamous epithelium that normally lines the distal oesophagus.
- Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. *The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus*. Am J Gastroenterol 2006 Aug;101(8):1900-20;
- Shaheen NJ, Richter JE. *Barrett's oesophagus*. Lancet 2009 Mar 7;373(9666):850-61



PRAGUE CRITERIA

For Endoscopically Suspected Esophageal Columnar Metaplasia/Barrett's Esophagus

Developed by the Barrett's Oesophagus Subgroup of the International Working Group for the Classification of Reflux Oesophagitis (IWGCO)




Diagrammatic representation of endoscopic Barrett's Oesophagus showing an area classified as C2M5. C: extent of circumferential metaplasia; M: maximal extent of the metaplasia (C plus a distal "tongue" of 3 cm); GEJ: gastroesophageal junction.

* To the nearest centimeter

Squamous and columnar islands do NOT contribute to measures of extent

† To the nearest centimeter, except when areas of columnar metaplasia are estimated to be less than 1 cm: report this as <1cm




HIATAL HERNIA


HIATAL HERNIA

- Two anatomic patterns are recognized: the **axial, or sliding** hernia and the **nonaxial, or paraesophageal** hernia.
- The **sliding hernia** constitutes 95% of cases; protrusion of the stomach above the diaphragm creates a bell-shaped dilation, bounded below by the diaphragmatic narrowing.
- In **paraesophageal hernias**, a separate portion of the stomach, usually along the greater curvature, enters the thorax through the widened foramen. The cause of this deranged anatomy is obscure.



Comparison of the two forms of esophageal hiatal hernias





ACALASIA

Achalasia

❖ **Achalasia** The term *achalasia* means "**failure to relax**" and in the present context denotes incomplete relaxation of the lower esophageal sphincter in response to swallowing.

❖ This produces functional obstruction of the esophagus, with consequent dilation of the more proximal esophagus.

• **Three major abnormalities in achalasia:**

(1) Aperistalsis (absence of peristalsis)

(2) partial or incomplete relaxation of the lower esophageal sphincter with swallowing

(3) increased resting tone of the lower esophageal sphincter.



Symptoms


- Backflow (regurgitation) of food
- Chest pain, which may increase after eating or may be felt in the back, neck, and arms
- Cough
- Difficulty swallowing liquids and solids
- Heartburn
- Unintentional weight loss

□ Examination

- Esophageal manometry: is a test used to measure the function of the lower esophageal sphincter by specific tube through esophagus to stomach
- Esophagogastroduodenoscopy
- Upper GI x-ray

Treatment

- The approach to treatment is to reduce the pressure at the lower esophageal sphincter.
- Therapy may involve:
- **Injection with botulinum toxin (Botox).** This may help relax the sphincter muscles, but any benefit wears off within a matter of weeks or months.
- Medications, such as long-acting nitrates or calcium channel blockers, which can be used to **relax** the lower esophagus sphincter.
- **Surgery** (called an esophagomyotomy), which may be needed to decrease the pressure in the lower sphincter.
- Widening (dilation or balloon) of the esophagus at the location of the narrowing (done during esophagogastroduodenoscopy).



ESOPHAGITIS

ESOPHAGITIS

- ❑ Injury to the esophageal mucosa with subsequent inflammation is a common condition worldwide. The inflammation may have many origins: prolonged gastric intubation, uremia, ingestion of corrosive or irritant substances, and radiation or chemotherapy.
- ❑ There are many presumed contributory factors:
 - ❑ Decreased efficacy of esophageal antireflux mechanisms
 - ❑ Inadequate or slowed esophageal clearance of refluxed material
 - ❑ The presence of a sliding hiatal hernia
 - ❑ Increased gastric volume, contributing to the volume of refluxed material
 - ❑ Impaired reparative capacity of the esophageal mucosa by prolonged exposure to gastric juices
- ❑ Any one of these influences may assume primacy in an individual case, but more than one is likely to be involved in most instances.